 |
|
            |
| Access educational resources for your patients to help them better understand and manage their CML. Learn more > |
| Since its development, Glivec® has been a cornerstone of therapy for CML patients. Learn more > |
Targeting the Molecular Causes of Chronic Myeloid Leukemia–CML Resources
The following Novartis websites contain information about targeted therapy for Ph+ CML that may be useful to you. ENEST (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) Glivec® (imatinib) International Site Tasigna® (nilotinib) International Site In this section, you can find additional resources to help you and your Ph+ CML patients stay up-to-date with current developments in the management of CML with targeted therapy. These include patient education and guidelines and recommendations from the National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN).Next: Patient Education |
|
See European Summary of Product Characteristics Glivec® 100 mg film coated tablets (PDF) Glivec® 400 mg film coated tablets (PDF) Glivec® 50 mg capsules, hard (PDF) Glivec® 100 mg capsules, hard (PDF)
About CML Alliance | Treating CML | Targeted Therapies and CML Contact | Site Map | Privacy |
© 2010 Novartis AG |